
There does not appear to be any comparative advantage for low-risk hematopoietic cell transplantation patients to seek care from high-risk centers.
There does not appear to be any comparative advantage for low-risk hematopoietic cell transplantation patients to seek care from high-risk centers.
The health benefits for participants of the Complete Health Improvement Program ("CHIP"), a lifestyle medicine program, are present regardless of the program tuition payment source.
An examination of socioeconomic disparities in cervical cancer screening across ethnic groups in the United States using concentration indices and probit regression analyses.
This study evaluates different strategies to identify high fall risk among community-dwelling elders using a combination of easily obtainable administrative data and patient screening questions.
Patient access to innovation may be at risk as new payment models emerge in oncology.
Initial medication filling during the first 2 to 4 months following initiation of a statin strongly predicted adherence patterns during the following year.
A decision-making framework that can be used to harmonize the evidence payer's desire for coverage and formulary decisions with the evidence generated by researchers.
Focusing on quality and quality measurements has the potential to reduce costs, increase quality, and deliver more value to patients, consumers, and customers.
Many patients with cancer desire cost discussions with doctors, but those discussions are rare. Nevertheless, cost discussions may lower patient costs-usually without altering treatment.
Description of a program embedding nonlicensed care coordinators in primary care practices including training, interventions, and the effect of the program on emergency department visits.
Many more patient than provider characteristics are associated with optimal or poor glycemic control and treatment intensification when glycemic control is initially lost.
Assessment of current trends, success factors, and challenges in the use of risk-sharing agreements in the US private sector.
To provide guidance for successful partnerships, the authors identify common themes from their experience with successful health plan/medical group partnerships programs.
259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.